Akèy › Limfom Difize Gwo Selil B › Oregon
Etid klinik pou Limfom Difize Gwo Selil B nan Oregon
16 etid pou Limfom Difize Gwo Selil B ap chèche patisipan nan sit nan Oregon.
Vil nan Oregon
Tèks ofisyèl etid la (Anglè)
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06649812A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Providence Portland Medical Center ( Site 0120), Portland
- Providence Oncology and Hematology Clinic Westside ( Site 0179), Portland
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06890884A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Kaiser Permanente Interstate Medical Office - Central ( Site 0181), Portland
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06717347Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
- OHSU Knight Cancer Institute, Portland
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06784167A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Oregon Health & Science University (OHSU), Portland
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07226843Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Oregon Health and Science University ( Site 1004), Portland
Ap rekriteFaz 1/2
6 Months – 25 Years · Tout sèks · Mizajou Sep 17, 2026 · NCT06395103Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Oncology Associates of Oregon, P.C, Eugene
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06806033Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Oncology Associates of Oregon, Eugene
- Oregon Health and Science University, Portland
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 31, 2026 · NCT06500273Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Oregon Health & Science University, Portland
Ap rekriteFaz 1/2
Laj 13 a 90 · Tout sèks · Mizajou Aug 6, 2026 · NCT06533579Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
- Oregon Health and Science University Knight Cancer Institute, Portland
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT06116110A Long-term Extension Study of PCI-32765 (Ibrutinib)
- Willamette Valley Cancer Center, Eugene
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT01804686DALY II USA/ MB-CART2019.1 for DLBCL
- Oregon Health and Science University Knight Cancer Institute, Portland
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT04792489Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma
- OHSU Knight Cancer Institute, Portland
Ap rekriteFaz 1/2
Laj 18 a 75 · Tout sèks · Mizajou Jul 7, 2026 · NCT06249191Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Providence Newberg Medical Center, Newberg
- Providence Willamette Falls Medical Center, Oregon City
- Providence Portland Medical Center, Portland
- ak 2 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Feb 2, 2026 · NCT05633615Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- Providence Newberg Medical Center, Newberg
- Providence Willamette Falls Medical Center, Oregon City
- Providence Portland Medical Center, Portland
- ak 1 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 20, 2025 · NCT05890352A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- Oregon Health & Science University, Portland
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2025 · NCT05780034Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.